ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Takeda sells 5 prescription drugs to China's Hasten for $322m

Blood pressure treatment Ebrantil part of Japanese company's latest asset sale

Japan's Takeda will sell off prescription drugs available in China, including the Ebrantil blood pressure reducer. (Photo by Nobuyoshi Shioda)

TOKYO -- Takeda Pharmaceutical will sell five prescription products to China's Hasten Biopharmaceutic in a $322 million deal as Japan's top drugmaker continues to slash debt from its acquisition of Ireland-based peer Shire.

The transaction is slated to close by the end of June and covers cardiovascular and metabolism treatments sold in mainland China, including the Ebrantil blood pressure reducer.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more